In Regard to Zelefsky et al.

Published on Jul 1, 2021in International Journal of Radiation Oncology Biology Physics7.038
· DOI :10.1016/J.IJROBP.2021.02.038
P. Berkovic3
Estimated H-index: 3
(Katholieke Universiteit Leuven)
Source
Abstract
References3
Newest
#1Michael J. Zelefsky (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 118
#2Yoshiya Yamada (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 71
Last. Zvi Fuks (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 129
view all 12 authors...
Abstract Purpose This prospective phase III randomized trial was designed to test whether ultra-high single-dose radiotherapy (24 Gy SDRT) improves local control of oligometastatic lesions over a standard hypofractionated stereotactic body radiotherapy regimen (3 x 9 Gy SBRT). The secondary endpoint was to assess the associated toxicity and the impact of ablation on clinical patterns of metastatic progression. Methods and Materials Between November 2010 and September 2015, 117 patients with 154 ...
Source
#1Carole Mercier (University of Antwerp)H-Index: 4
#2Michaël Claessens (University of Antwerp)H-Index: 3
Last. Piet Dirix (University of Antwerp)H-Index: 27
view all 14 authors...
Purpose Increasing evidence suggests that patients with a limited number of metastases benefit from SABR to all lesions. However, the optimal dose and fractionation remain unknown. This is particularly true for bone and lymph node metastases. Therefore, a prospective, single-center, dose-escalation trial was initiated. Methods Dose-Escalation trial of STereotactic ablative body RadiOtherapY for non-spine bone and lymph node metastases (DESTROY) was an open-label phase 1 trial evaluating SABR to ...
Source
#1Akira Komiya (University of Toyama)H-Index: 9
#2Masaki ShimboH-Index: 13
Last. Tomohiko IchikawaH-Index: 58
view all 10 authors...
We retrospectively evaluated the outcome of oral low-dose dexamethasone (DXM) therapy for androgen-independent prostate cancer (AIPC). Between January 1999 and April 2006, 99 consecutive patients with AIPC were enrolled in this study. The median patient age was 70 years (range 46–86), and the median pretreatment prostate-specific antigen (PSA) level was 243 ng/ml (range 8.2–29600). Median follow-up was 41.9 months (range 11.4–170.4). Upon biochemical failure, patients were treated with oral low-...
Source
Cited By1
Newest
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.